Advertisement

 

 

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.

Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C.
Author Information (click to view)

Greig SL,


Greig SL, (click to view)

Greig SL,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Drugs 2016 Oct 11()

Abstract

A once-daily, single-tablet, pangenotypic regimen comprising the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir and the HCV NS5A inhibitor velpatasvir (sofosbuvir/velpatasvir; Epclusa(®)) was recently approved for the treatment of adults with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in the USA, EU and Canada. In the phase III ASTRAL trials, once-daily oral sofosbuvir/velpatasvir for 12 weeks provided very high rates of sustained virological response at 12 weeks post treatment (SVR12) in treatment-naive and -experienced patients with chronic HCV genotype 1-6 infection, including those with compensated cirrhosis or HIV-1 co-infection. High SVR12 rates were also observed with sofosbuvir/velpatasvir plus ribavirin for 12 weeks in patients with chronic HCV genotype 1-6 infection and decompensated cirrhosis. Sofosbuvir/velpatasvir was generally well tolerated, with low rates of adverse events. Thus, sofosbuvir/velpatasvir represents a valuable treatment option in adults with chronic HCV genotype 1-6 infection, including those with compensated or decompensated cirrhosis, previous treatment experience or HIV-1 co-infection.

Submit a Comment

Your email address will not be published. Required fields are marked *

three × three =

[ HIDE/SHOW ]